Daily Market BriefHealthcare

AbbVie Expands Portfolio with $10.9B Apogee Deal

Major M&A activity highlights Big Pharma dealmaking as European approvals expand therapeutic reach

Money365.Market AI
3 min read
Market MoodRisk-On
Sentiment+65Bullish

Key DriverAbbVie's $10.9 billion Apogee Therapeutics acquisition at 49% premium signals continued Big Pharma M&A momentum

Today in 30 Seconds

  • AbbVie acquires Apogee Therapeutics for $10.9B at 49% premium to par value
  • European Commission approves MAVIRET for acute HCV and SKYRIZI for pediatrics
  • Pfizer's sigvotatug vedotin misses primary endpoint in Phase 3 lung cancer trial
All Briefs

Big Pharma M&A Activity

Bullish

Apogee Deal Value

$10.9B

Offer Premium

49%

Price Per Share

$135.11
$ABBV

AbbVie ($ABBV) announced a $10.9 billion cash acquisition offer for Apogee Therapeutics at $135.11 per share, representing a 49% premium. The deal contributes to what sources describe as a $200 billion pharmaceutical M&A spree underway in the sector. Wells Fargo maintained an Overweight rating on $ABBV with a $260 price target, citing value in the Apogee acquisition. The transaction underscores Big Pharma's aggressive pursuit of late-stage pipeline assets to address patent cliff concerns and expand therapeutic portfolios.

European Regulatory Approvals

Bullish

SKYRIZI Dosage Form

55 mg
$ABBV$ENTA

The European Commission granted $ABBV approval for MAVIRET (glecaprevir/pibrentasvir) to treat acute hepatitis C virus infection in adults and children aged 3 years and older, making it the only treatment approved in the European Union for both acute and chronic HCV infection. Separately, the EC approved SKYRIZI (risankizumab) for treating moderate to severe plaque psoriasis in children and adolescents six years and older who are candidates for systemic therapy. The approval includes a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg. Enanta Pharmaceuticals ($ENTA), which partnered with $ABBV on MAVIRET, announced the acute HCV approval extends the drug's therapeutic reach in European markets.

Clinical Trial Readouts

Bearish
$PFE

Pfizer ($PFE) announced topline results from the Phase 3 SigVie-002 study evaluating sigvotatug vedotin, an investigational integrin beta-6 directed antibody-drug conjugate, in adults with locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer who had received one or more lines of prior therapy. In the overall population, sigvotatug vedotin did not demonstrate a statistically significant improvement in overall survival compared with chemotherapy medicine docetaxel. The mixed results for the Seagen-origin cancer drug represent a setback for $PFE's oncology pipeline expansion following its Seagen acquisition.

Biotech Funding & Partnerships

Bullish

TRIMTECH Total Seed Round

$47M

Latest Investment

$14M
$JNJ$LLY

TRIMTECH Therapeutics raised an additional $14 million in seed funding, bringing the total seed round to $47 million (£35 million), to develop TRIMTAC and TRIMGLUE targeted protein degradation therapies for neurodegenerative diseases. The financing was led by Johnson & Johnson ($JNJ) Innovation – JJDC, Inc., the company's corporate venture capital organization. Separately, Eli Lilly ($LLY) signed a deal with BioArctic to develop a neurodegenerative therapy, with BioArctic creating a new drug candidate using its BrainTransporter platform and $LLY's molecule. These partnerships reflect continued investment in novel neuroscience platforms amid an aging global population.

Patent Damages Awarded

$20,203,704
$AMGN

A Delaware jury ruled that Amgen ($AMGN) and its subsidiary Teneobio willfully infringed Harbour BioMed's Grosveld patent, awarding Harbour $20,203,704 in damages with the option to seek a tripling of that amount. The verdict in one of the most closely watched antibody technology patent disputes highlights legal and financial exposure around $AMGN's antibody discovery platforms and broader intellectual property posture. The willful infringement finding could result in enhanced damages significantly exceeding the initial award, creating uncertainty for investors evaluating the company's antibody therapeutic pipeline.

Risk Flags

WatchPfizer's sigvotatug vedotin failed primary endpoint in Phase 3 lung cancer trial
AlertAmgen faces potential tripling of $20.2M patent damages for willful infringement

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy

Back to All Briefs